Suven Life Sciences Ltd

Stage 3 · Topping · week 1

As of 16 Oct 2026, Suven Life Sciences is in Stage 3 — topping, where an uptrend loses steam, in its first week (since 12 Oct 2026). It closed at ₹304, 22.6% below its 52-week high and above its 200-day average, which is rising. In Health Care, 40.6% of stocks are in Stage 2.

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative dis… More about the company

₹303.6
+1.10% today
₹8,577 Cr · Mid cap
Market Neutral — FadingHealth Care 40.6% in Stage 2-7.4 pts / 20dPharmaceuticals 50.4%-2.5 pts

Pro read

Pro

Our read

Topping — the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is SUVEN early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-22.6%
₹126.7 lo₹392.1 hi
22.6% below 52W high — weakening from peak
Stock is rolling over from its 52W high. Stage 3 distribution — new longs are high risk here.
Stage Maturity
Week 1
1w13w26w
Week 1 — early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
24.6%
200 DMA: ₹243.6 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.70x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution — institutions are exiting. A clear warning to avoid new longs.
Trend Health
↓
MA20 rolling over · -9.4% vs MA50 -1.6%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-9.8%
3M
-6.9%
6M
+54.9%
YTD
+76.8%
1Y
+50.9%
Sector
Health Care
↓ Peaking
Stage 2%
40.6%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
Sector has 67 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
50.4%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Industry has 57 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2023-07-20 → 2026-10-16
S2 39w
S2 15w
S2 15w
S4 19w
S2 20w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 39w → S3 2w → S2 2w → S3 8w → S2 15w → S3 10w → S2 5w → S3 1w → S4 10w → S1 2w → S2 15w → S3 13w → S4 19w → S1 5w → S2 20w → S3 1w current
Total tracked: 168 weeks across 16 stage runs.
Scan Membership
Prop Scan
Latest: 2026-09-17
Pullback Hunter
Latest: 2026-08-19
60 appearances in last 60 days. First seen: 2026-07-22.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding — staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-16S3
Wk 1 · Vol 0.70x
2026-10-15S3
Wk 1 · Vol 5.11x
2026-10-14S3
Wk 1 · Vol 0.54x
2026-10-13S3
Wk 1 · Vol 0.79x
2026-10-12S32→3
Wk 1 · Vol 0.97x
2026-10-09S2
Wk 20 · Vol 0.83x
2026-10-08S2
Wk 20 · Vol 0.83x
2026-10-07S2
Wk 20 · Vol 0.43x
2026-10-06S2
Wk 19 · Vol 1.30x
2026-10-05S2
Wk 19 · Vol 0.42x
2026-10-01S2
Wk 19 · Vol 0.99x
2026-09-30S2
Wk 19 · Vol 0.56x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹337.9
200 DMA
₹243.6
52W High
₹392.1
52W Low
₹126.7
5D Low
₹283.8
Resistance levels (recent highs)
20d High
₹341.9
60d High
₹392.1
120d High
₹392.1
250d High
₹392.1
Next resistance
+12.6%
to 20d High
Ask the Market AI about SUVENAsk →
ROE
-78.8%
Profit margin 0.0%
About this companyHealth Care· Pharmaceuticals

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for treating sleep and cognitive disorders; and Ropanicant (SUVN-911), an Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is also developing Usmarapride (SUVN-D4010), a bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for treating cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for treating gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is based in Hyderabad, India. Suven Life Sciences Limited operates as a subsidiary of Jasti Property and Equity Holdings Private Limited.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.